Amiloride News and Research RSS Feed - Amiloride News and Research

FDA accepts Merck's JANUMET extended-release formulation NDA for type 2 diabetes

FDA accepts Merck's JANUMET extended-release formulation NDA for type 2 diabetes

Merck today announced that the New Drug Application (NDA) for the Company's investigational extended-release formulation of JANUMET for type 2 diabetes has been accepted for standard review by the U.S. Food and Drug Administration (FDA). The Company is also moving forward as planned with regulatory filings in countries outside the United States. [More]
JANUMET results in greater blood sugar reductions in patients with type 2 diabetes compared to pioglitazone

JANUMET results in greater blood sugar reductions in patients with type 2 diabetes compared to pioglitazone

New data were presented at the American Diabetes Association 70th Annual Scientific Sessions from a study comparing JANUMET (sitagliptin/metformin) to pioglitazone. In this study, JANUMET resulted in significantly greater blood sugar reductions in patients with type 2 diabetes compared with pioglitazone. [More]
Hemodynamic Therapeutics' HTI-101 clinical study for treatment-resistant hypertension meets primary endpoint

Hemodynamic Therapeutics' HTI-101 clinical study for treatment-resistant hypertension meets primary endpoint

Hemodynamic Therapeutics, Inc. (HTI), a portfolio company of Cato BioVentures, announces the successful completion of its initial Phase 2 clinical study of its lead compound ("HTI-101"), a patented low-dose small-molecule investigational therapy intended for patients with treatment-resistant hypertension. [More]
Safety profiles of JANUVIA and JANUMET drugs established through clinical development program

Safety profiles of JANUVIA and JANUMET drugs established through clinical development program

Merck has thoroughly reviewed the safety data for sitagliptin, and sitagliptin was not associated with an increase in the incidence of pancreatitis in preclinical studies or in clinical trials of up to two years in duration with more than 6,000 patients. [More]
European CHMP recommends Merck's JANUVIA and JANUMET as add-on to insulin

European CHMP recommends Merck's JANUVIA and JANUMET as add-on to insulin

Merck & Co., Inc., which operates in many countries as Merck Sharp & Dohme (MSD), has received a positive opinion from the European Medicines Agency’s (EMEA) Committee for Medicinal Products for Human Use (CHMP) for JANUVIA® tablets and JANUMET® tablets recommending their use as add-on to insulin for the treatment of type 2 diabetes. [More]

Sodium channel-blocking agent shows promise as a potential treatment for cystic fibrosis

Cystic fibrosis patients may benefit from a new therapy that increases airway hydration, preventing the buildup of mucous, which is a key factor in the disease, according to researchers at Parion Sciences in Durham, N.C. [More]
New target for MS treatment found using old drug

New target for MS treatment found using old drug

A drug currently used to treat high blood pressure and heart failure has been found to reduce the symptoms of multiple sclerosis in mice. [More]
Hypertension drugs may prevent Alzheimer's Disease

Hypertension drugs may prevent Alzheimer's Disease

New research is suggesting that some of the drugs commonly used to treat hypertension (high blood pressure) may offer another benefit. [More]
Salt water treatment for cystic fibrosis both effective and cheap

Salt water treatment for cystic fibrosis both effective and cheap

Two teams of scientists working half a world apart, have identified what they believe is a simple, effective and inexpensive treatment to reduce lung problems associated with cystic fibrosis. [More]

Amiloride and spironolactone may help patients with high blood pressure

Two inexpensive but widely overlooked drugs may help many patients who continue to have high blood pressure despite taking standard blood pressure medications, according to research by Indiana University School of Medicine scientists. [More]
New culprit behind the brain injury suffered by stroke victims

New culprit behind the brain injury suffered by stroke victims

Researchers have uncovered a new culprit behind the brain injury suffered by stroke victims. Their new study, published in the Sept. 17 issue of Cell, links brain cell damage to a rise in brain acidity following the oxygen depletion, or ischemia, characteristic of stroke. [More]